fbpx
Request Support
Request Info
Resources|Area of Interest|Corporate Information|Tech Talk: What makes Xstrahl unique?

Tech Talk: What makes Xstrahl unique?

July 26, 2021

What makes Xstrahl unique in the world of radiation? Hear from our CEO, Adrian Treverton on how Xstrahl connects leading researchers and clinicians, and paves the way for radiation innovation with our incredible team.

Contact Us

Find out more about why Xstrahl will work tirelessly for you

Contact Us

Explore Related Posts

Xstrahl to feature Radiant™ Aura at ASTRO 2023

Xstrahl to feature Radiant™ Aura at ASTRO 2023

Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, will demonstrate Radiant Aura, a new low-dose, X-ray based, dual modality radiation therapy for treating non-melanoma skin cancers (NMSC) and keloid scarring at the American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting in San Diego, CA, October 1-3, 2023, booth #2216.

read more
Radiant™ Aura Receives U.S. Food and Drug Administration (FDA) 510(k) Clearance

Radiant™ Aura Receives U.S. Food and Drug Administration (FDA) 510(k) Clearance

Radiant™ Aura Receives U.S. Food and Drug Administration (FDA) 510(k) Clearance
Expands office-based treatment options for millions of non-melanoma skin cancer (NMSC) patients
Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, announced its Radiant™ Aura treatment solution has received U.S. Food and Drug Administration (FDA) 510(k) clearance. With advanced features for expanded clinical use, simplified patient positioning, and additional patient comfort, Radiant Aura brings radiation therapy to NMSC patients in any dermatology office. 

read more